Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

NCT01955629 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped The study enrollment was prematurely halted due to safety reasons.

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Aflibercept AVE0005
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Sanofi

Collaborators

[object Object]